Vaginal estrogen + Placebo
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Organ Prolapse
Conditions
Pelvic Organ Prolapse
Trial Timeline
May 1, 2012 → Mar 2, 2023
NCT ID
NCT01648751About Vaginal estrogen + Placebo
Vaginal estrogen + Placebo is a pre-clinical stage product being developed by Pfizer for Pelvic Organ Prolapse. The current trial status is terminated. This product is registered under clinical trial identifier NCT01648751. Target conditions include Pelvic Organ Prolapse.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01648751 | Pre-clinical | Terminated |
Competing Products
11 competing products in Pelvic Organ Prolapse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 85 |
| BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 51 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 84 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 30 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 74 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |